Sanofi reports positive data from Phase II asthma treatment trial

Sanofi has announced positive outcomes from a Phase II clinical trial of rilzabrutinib, an oral treatment for adults with uncontrolled moderate-to-severe asthma.

The double-blind, randomised, placebo-controlled, parallel-group trial analysed the safety, tolerability and efficacy of rilzabrutinib over 12 weeks.